Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy
the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called
a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced
treatment regimen to decrease the number of resting CD4 cells that become infected with HIV.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)